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Abstract
Objective
To describe the clinical and functional consequences of 1 novel and 1 previously reported
truncating MT-ATP6 mutation.
Methods
Three unrelated probands with mitochondrial encephalomyopathy harboring truncating MT-
ATP6 mutations are reported. Transmitochondrial cybrid cell studies were used to conﬁrm
pathogenicity of 1 novel variant, and the eﬀects of all 3 mutations on ATPase 6 and complex V
structure and function were investigated.
Results
Patient 1 presented with adult-onset cerebellar ataxia, chronic kidney disease, and diabetes,
whereas patient 2 had myoclonic epilepsy and cerebellar ataxia; both harbored the novel
m.8782G>A; p.(Gly86*) mutation. Patient 3 exhibited cognitive decline, with posterior white
matter abnormalities on brain MRI, and severely impaired renal function requiring trans-
plantation. The m.8618dup; p.(Thr33Hisfs*32) mutation, previously associated with neurogenic
muscle weakness, ataxia, and retinitis pigmentosa, was identiﬁed. All 3 probands demonstrated
a broad range of heteroplasmy across diﬀerent tissue types. Blue-native gel electrophoresis of
cultured ﬁbroblasts and skeletal muscle tissue conﬁrmed multiple bands, suggestive of impaired
complex V assembly. Microscale oxygraphy showed reduced basal respiration and adenosine
triphosphate synthesis, while reactive oxygen species generation was increased. Trans-
mitochondrial cybrid cell lines studies conﬁrmed the deleterious eﬀects of the novelm.8782G>A;
p.(Gly86*) mutation.
Conclusions
We expand the clinical and molecular spectrum of MT-ATP6-related mitochondrial disorders
to include leukodystrophy, renal disease, and myoclonic epilepsy with cerebellar ataxia.
Truncating MT-ATP6 mutations may exhibit highly variable mutant levels across diﬀerent
tissue types, an important consideration during genetic counseling.
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Mitochondrial disorders are genetic diseases caused by muta-
tions in mitochondrial DNA (mtDNA)-encoded or nuclear-
encoded genes; the protein products of which are essential for
adenosine triphosphate (ATP) synthesis by oxidative phos-
phorylation (OXPHOS). ATP is generated from adenosine
diphosphate and inorganic phosphate by mitochondrial ATP
synthase (OXPHOS complex V), which harnesses the proton
electrochemical gradient generated across the inner mito-
chondrial membrane by the sequential transfer of electrons
across the mitochondrial electron transport chain enzymes
(complexes I–IV).1 ATP synthase comprises 16 subunits, 14
nuclear-encoded and 2 mtDNA-encoded (MT-ATP6/8). Nu-
merous pathogenic mutations in MT-ATP6/8 are reported.
The most common of these is the pathogenic m.8993T>G/C
mutation in MT-ATP6, encoding the ATP6 subunit of mito-
chondrial ATP synthase, which is proven to both disrupt as-
sembly of complex V and reduce catalytic activity of the
enzyme.2 Classic mitochondrial phenotypes described with
MT-ATP6 mutations include maternally inherited Leigh syn-
drome and neurogenic muscle weakness, ataxia, and retinitis
pigmentosa (NARP). The presentation and severity of these
are usually dependent on the level of mutant mtDNA (heter-
oplasmic load) in diﬀerent tissue types.3 Recently, the clinical
spectrum of mitochondrial ATP synthase disorders has ex-
panded further to include axonal Charcot-Marie-Tooth dis-
ease,4 late-onset hereditary spastic paraplegia-like disorder,5
and episodic weakness.6 The majority of MT-ATP6 mutations
are missense; only 3 truncating mutations are reported, all of
which presented with ataxia, developmental delay, orNARP.7–9
Here, we describe 3 patients harboring heteroplasmic trun-
cating MT-ATP6 mutations; 2 harboring a novel de novo
variant and a third with a maternally inherited, previously
reported, mutation. The structural and functional con-
sequences of both mutations in all the 3 patients are presented.
Methods
Standard protocol approvals, registrations,
and patient consents
The study was performed under the ethical guidelines issued by
the relevant local ethical committees of the participating cen-
ters with written informed consent obtained from participants.
Patient 1
The proband (P1), a 37-year-old man, is the eldest of 2 sib-
lings from nonconsanguineous parents. Intrauterine growth
restriction was reported, but early motor development was
otherwise normal. At 10 years of age, growth hormone re-
placement was commenced for short stature. He subsequently
developed noninsulin-dependent diabetes at the age of 24
years and was diagnosed with focal segmental glomerulo-
sclerosis 1 year later. He subsequently developed imbalance
(28 years), sensorineural hearing loss (30 years), impaired
exercise tolerance and muscle aches/cramps (34 years), and
complex partial seizures (36 years). There is no family history;
both parents and his 27-year-old sister are healthy (ﬁgure 1A).
Clinical examination at the age of 36 years revealed short
stature (5 feet 5 inches), microcephaly, a mild head tremor, an
ataxic gait, bilateral sensorineural hearing loss, and impaired
coordination. There were upper motor neuron signs in the
limbs, with increased tone and pathologically brisk reﬂexes.
Blood lactate at the age of 35 years was elevated (4.66 IU/L,
reference range 0.5–2.2). Nerve conduction studies and EMG
showed no evidence of neuropathy or myopathy. EEG was
normal. Brain MRI showed left sided mesial temporal scle-
rosis, cerebellar atrophy, and white matter changes (ﬁgure
1A). Diagnostic next generation sequencing (NGS) of
mtDNA in blood conﬁrmed the novel heteroplasmic trun-
cating MT-ATP6 variant m.8782G>A; p.(Gly86*). Mutant
m.8782G>A; p.(Gly86*) levels varied across the tissues, with
31%mutant load detected in blood leucocytes, 53% in urinary
epithelial cells, and 27% in primary ﬁbroblasts. The variant
was undetectable in mtDNA extracted from the blood leu-
cocytes of the P1’s asymptomatic mother (ﬁgure 1A).
Patient 2
The proband (P2) is a 38-year-old woman born after un-
complicated pregnancy and delivery from Italian non-
consanguineous parents. Cognitive impairment was reported
in late infancy. At 25 years of age, she had frequent episodic
jerks and tremors of the arms and legs and was diagnosed with
myoclonic epilepsy at the age of 32 years. At 36 years of age,
she underwent bilateral cataract surgery. She had also de-
veloped gait instability, speech impairment, hearing loss, and
tinnitus. Her mother was reported to have migraine, focal-
onset epilepsy with a normal brain MRI, type 2 diabetes, and
lipomas. The proband was the second born of 4 children; the
eldest brother died at 3 months of age for a not speciﬁed
cardiomyopathy. Both her 31-year-old brother and 16-year-
old sister are healthy (ﬁgure 1B). Clinical examination of the
proband at the age of 38 years showed short stature, hyper-
trichosis, dysarthria, nystagmus in lateral gaze, upper limb
tremor, dysmetria, and ataxic gait. ECG and echocardiogram
Glossary
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were normal. Pure tone audiometry conﬁrmed sensorineural
hearing loss. EEG conﬁrmed epileptic myoclonus, and no
myopathic changes were found in the EMG. Brain CT
showed basal ganglia calciﬁcation. Brain MRI performed at
the age of 38 years demonstrated cerebellar atrophy, brain-
stem atrophy, and mild white matter abnormalities (ﬁgure
1B), and spectroscopy detected a peak of lactate in the cer-
ebellum voxel. Muscle biopsy showed mild myopathic fea-
tures with a single cytochrome c oxidase (COX) deﬁcient
ragged red ﬁber (RRF). Spectrophotometric assays of mito-
chondrial respiratory chain (RC) complexes I–IV in muscle
and complexes I–V in ﬁbroblast, normalized for citrate syn-
thase (CS) activity, was normal.
NGS of the entire mitochondrial genome detected the
m.8782G>A: p.(Gly86*) variant in MT-ATP6; it was present
at 71% mutant load in skeletal muscle tissue, 11% in blood,
28% in urinary epithelial cells, and 12% in ﬁbroblasts. The
mutation was considered de novo in the proband, given that it
was undetectable in maternal blood lymphocytes, urinary
epithelial cells, and skeletal muscle tissue.
Patient 3
The proband (P3), a 42-year-old woman, was the eldest of 3
siblings from nonconsanguineous parents. She was born at
term without any pregnancy complications. She presented to
pediatric medical services in early infancy with failure to
thrive, because of feeding diﬃculties, and global de-
velopmental delay; she walked at 18 months, but gait was
poorly coordinated, and she was never able to keep up with
peers when running. During adolescence, she developed
scoliosis, bilateral cataracts, tapetoretinal degeneration, and
mild aortic regurgitation. At 23 years of age, she was di-
agnosed with learning diﬃculties and Asperger syndrome.
Sensorineural deafness was detected at the age of 30 years,
followed by chronic kidney disease, which was treated ini-
tially with hemodialysis, followed by a renal transplant, at the
age of 31 years. At 32 years of age, she had surgery for
bilateral cataracts and developed diabetes at 38 years, which
is now managed with insulin. More recently, she has de-
veloped dysphagia and cognitive decline. Owing to pro-
gressive imbalance, she now requires a wheelchair for long
distances. There was no family history for neurologic or
multisystem disease (ﬁgure 1C). Clinical examination at the
age of 36 years conﬁrmed an ataxic, spastic gait and short
stature (4 feet 8 inches). Cranial nerve examination revealed
reduced upgaze, dysarthria, and slow tongue movements. In
the limbs, there was a mild bilateral postural tremor, in-
creased tone, and brisk reﬂexes with normal sensation. Blood
lactate was mildly elevated (2.59 mmol/L, reference range
0.5–2.2). Brain MRI showed white matter changes and
cerebellar atrophy (ﬁgure 1C). Muscle biopsy showed mild
Figure 1 Pedigrees and brain MRI findings
(A.a) Family pedigree chart of patient 1
(P1) harboringm.8782 G>A; p.(Gly86*)
mutation. Brain MRI showing cerebel-
lar atrophy (red arrowhead, A.b) and
multiple deep and periventricular
white matter changes (red arrow-
heads, A.c). (B.a) Family pedigree chart
of patient 2 (P2) harboring
m.8782G>A; p.(Gly86*) mutation.
Brian MRI showing reduced brain vol-
ume, marked global cerebellar, and
brainstem atrophy (red arrowhead,
B.b) and multiple deep and periven-
tricular white matter changes (red
arrowheads, B.c). (C.a) Family pedi-
gree chart of patient 3 (P3) harboring
m.8618dup; p.(Thr33Hisfs*32) muta-
tion. Brain MRI showing severe cere-
bellar atrophy (red arrowhead, C.b)
and posterior white matter abnor-
malities (red arrowheads, C.c). Elec-
tron microscopy showing several
mitochondria with simplified internal
structure (C.d). High magnification
(C.e) showing a mitochondria with
aberrant cristae formation. Scale bar
represents 200 nm. Filled symbols in-
dicate affected individuals. Symbols
with diagonal strikethrough indicate
deceased. Arrows indicate probands.
Mutation load detectable in different
tissues: B = blood; F = fibroblasts; M =
muscle; U = urine.
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myopathic features and increased lipid content with no RRF
or COX deﬁcient ﬁbers. Electron microscopy (EM) showed
several, scattered mitochondria with abnormalities in the
cristae (ﬁgure 1C). Spectrophotometric assays of mito-
chondrial RC complexes I and IV in the muscle, corrected
for CS, was normal. Enzyme assay of complex II + III
(succinate: cytochrome c reductase) revealed reduced ac-
tivity (complex II + III/CS ratio 0.018, reference range
0.04–0.204). However, subsequent analysis of complex II
and muscle ubiquinone was normal (complex II/CS 0.097,
reference range 0.052–0.25, ubiquinone 237 pmol/mg, refer-
ence range 140–580 pmol/mg). Array comparative genomic
hybridization analysis was normal. NGS of mtDNA conﬁrmed
the previously reported heteroplasmic truncating MT-ATP6
mutation, m.8618dup; p.(Thr33Hisfs*32).7Mutant m.8618dup;
p.(Thr33Hisfs*32) levels were conﬁrmed across multiple tissues.
These included 20% in blood leucocytes, 45% in primary
ﬁbroblasts, and 65% inmuscle tissue. Themutationwas detected
in other unaﬀected family members at substantially lower levels
(ﬁgure 1C).
After identiﬁcation of the 2 heteroplasmic truncating MT-
ATP6 mutations, experiments to conﬁrm their downstream
pathologic eﬀects on mitochondrial ATP synthase structure
and function were undertaken, using patient-derived mutant
ﬁbroblasts (P1 and P3), transmitochondrial cybrids (obtained
from mutant ﬁbroblast P2) and muscle samples (P2 and P3).
Cell culture
Primary ﬁbroblast cultures were obtained from healthy con-
trols and patients (P1, P2, and P3). Human ﬁbroblasts were
grown either in Dulbecco’s Modiﬁed Eagle Medium with
4.5 g/L glucose, 10% fetal calf serum, 1 mM sodium pyruvate,
200 U/mL penicillin G, and 200 mg/mL streptomycin or in
an equivalent medium in which glucose was replaced by 5mM
galactose, at 37°C in a humidiﬁed 5% CO2 atmosphere.
Cybrids were obtained from P2 as previously described10,11
(e-methods 1 and ﬁgure e-1, links.lww.com/NXG/A201).
Blue-native gel electrophoresis
Blue-native gel electrophoresis (BNGE) on ﬁbroblast (P1 and
P3) and muscle (P2 and P3) samples was performed as pre-
viously described.12,13Mitochondria were solubilizedwith either
n-dodecyl-β-d-maltoside (DDM), 1.6 mg/mg of mitochondrial
protein or digitonin 4 mg/mg of mitochondrial protein.13
Samples were run on precast native polyacrylamide 3%–12%
Bis-Tris gels. Proteins were either transferred on a nitrocellulose
membrane (1D-BNGE) or denatured and run on SDS-PAGE
(2D-BNGE). Anti-ATP5A (Abcam, ab14748), anti-ATP6
(Abcam ab219825), and anti-COXIV (Abcam, ab14744) anti-
bodies were used for complex V and complex IV visualization.
Western blot
Mitochondrial-enriched fractions from the muscle (P2 and
P3) were separated by denaturing NuPAGE 4%–12% Bis-Tris
gels and blotted with anti-ATP6 (Abcam ab219825) and anti-
VDAC1/porin (Abcam, ab154856) antibodies.
Microscale oxygraphy
The oxygen consumption rate (OCR) was measured in ad-
herent ﬁbroblasts (P1 and P3) with a XF96 Extracellular Flux
Analyzer (Seahorse Bioscience, Billerica, MA). Control and
mutant ﬁbroblast cell lines were seeded in 8–12 wells of a XF
96-well cell culture microplate (Seahorse Bioscience) at
a density of 15–20 × 103 cells/well and analyzed after 24
hours. OCR was measured at baseline and after sequentially
adding of 1 μM oligomycin A, 1 μM of carbonyl cyanide 4-
(triﬂuoromethoxy) phenylhydrazone, and 1 μM of rotenone
and antimycin A (protocol available on request). Normali-
zation was performed with a CyQUANT Cell Proliferation
Assay Kit (Thermo Fisher Scientiﬁc, cat. No. C35007),
according to the manufacturer’s instructions.
Reactive oxygen species measurement
Reactive oxygen species (ROS) were measured on patients’
ﬁbroblasts (P1 and P3). Cells were seeded in 15–20 × 103
cells/well in 96-well plate and used after 24 hours. Cells were
washed with PBS and incubated for 30 minutes with 100 μM
of CM-H2DCFDA (Thermo Fisher Scientiﬁc, cat. N.
C6827), and then, ﬂuorescence was recorded for 30 minutes
with Ex 488/Em 525 nm. Equal numbers of cells were seeded
in a separate 96-well plate and normalization was performed
as previously mentioned.
Statistical analysis
All numerical data are expressed as mean ± SEM. After as-
sessment for normality Student unpaired 2-tail t test was used
for statistical analysis of the OCR data, whereas paired t test
was used for statistical analysis of the ROS data. Diﬀerences
were considered statistically signiﬁcant for p ≤ 0.05.
Data availability
The data that support the ﬁndings of this study are available
on request from any qualiﬁed investigator.
Results
Deleterious effects of them.8782G>Amutation
in cybrids with high mutant load
The RC activity on ﬁbroblasts in 12% mutated clones was
normal for all complexes (CI-CV). The RC on trans-
mitochondrial cybrids in 0% and in 10% mutated clones was
normal while a severe reduction of complex Vwas revealed in the
95%mutated clone (29.10, 28.90, and 8.30 nmol/min per mg of
protein for 0%, 10%, and 95% mutated cybrids, respectively).
Impaired complex V assembly
Complex V assembly defect was present in DDM-solubilized
mitochondria from both the patient-derived ﬁbroblasts (P1 and
P3); according to the mutant load, P3 was more severely af-
fected than P1 (45% vs 27%, ﬁgure 2A).Mutations in theATP6
gene resulted in accumulation of F1 subcomplexes (x, y, and z)
14 that were detectable using an antibody to ATP5A, the early
assembled ATP synthase F1 subunit α (ﬁgure 2A). Complex
intermediates were also demonstrated in muscle samples (P2
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and P3, ﬁgure 2B). Notably, fully assembled complex V was
detectable in patients and 2D-BNGE conﬁrmed that residual
ATP6 protein was indeed incorporated into complex V
(ﬁgure 2, C and D). Similar results were obtained in samples
solubilized with digitonin (not shown). ATP6 levels in the
2D BNGE performed in the muscle were reduced compared
with the control (ﬁgure 2D) in agreement with the mutant
load found in this tissue (71% in P2 and 65% in P3). We
evaluated the steady state level of ATP6 protein in muscle
samples, and we conﬁrmed a reduction of ≈40% in both
patients (ﬁgure 2, E and F).
Reduced basal respiration and ATP synthesis
Both P1 and P3 mutant ﬁbroblasts demonstrated reduced
OCR and ATP production in basal conditions (Figure 3,
A–D). The latter was more pronounced in the ﬁbroblasts of
P3, which harbored higher MT-ATP6 mutation levels (27%
and 45% mutant load in P1 and P3, respectively). Maximal
respiratory capacity was not statistically diﬀerent in control
when compared with mutant ﬁbroblasts (ﬁgure 3C).
Increased reactive oxygen species
ROS production was signiﬁcantly higher (+19% P1, p < 0.01
and +20% P3, p < 0.05, at T = 0, ﬁgure 3E), and the rate of
ROS production (measured over 30 minutes) was greater in
the patient-derived ﬁbroblasts compared with the controls
(4.66 A.U./min P1 and 4.73 A.U./min P3 vs 3.66 A.U./min
control, p < 0.0005 for P1 and P3, ﬁgure 3E). There was no
Figure 2 One-dimensional and 2-dimensional BNGE
(A and B) Immunovisualization of complex V in 1-dimensional BNGE of
enriched mitochondria fractions extracted from fibroblasts and muscles
and solubilized with DDM. Control (C), patient 1 (P1), patient 2 (P2), and
patient 3 (P3) are shown. Three F1 x, y, and z subcomplexes are present in
fibroblasts of P1 and P3, whereas only 2 of 3 subassemblies are present in
the muscle of P3 and P2. See discussion for details. Anti-ATP5A and anti-
COXIV used to visualize complex V and complex IV, respectively. (C and D)
Denaturing 2-dimensional BNGE of enriched mitochondria fractions
extracted from fibroblasts and muscle and solubilized with DDM con-
firmed the presence of ATP synthase subcomplexes in P1, P2, and P3.
Residual ATP6 protein is found incorporated into the fully assembled
complex V in P1, P2, and P3. (E) Western blot of muscle samples show
reduced ATP6 protein in patients (P2, P3) compared with the control. (F)
Densitometry analysis of (E) performed in 2 different experiments. Values
are normalized to controls. Error bars represent SEM. ATP = adenosine
triphosphate; BNGE = blue-native gel electrophoresis; CIV = complex IV;
COXIV = cytochrome c oxidase IV; CTR = control; CV = complex V; DDM = n-
dodecyl-β-d-maltoside; MW = molecular weight; SDS-PAGE = sodium
dodecyl sulfate-polyacrylamide gel electrophoresis; SEM = standard error
of the mean; VDAC1 = voltage dependent anion channel 1.
Figure 3Microscale oxygraphy and reactive oxygen species
measurement
(A) Representative graph illustrating the protocol used tomeasuremitochondrial
respiration in fibroblasts using a XF96 extracellular flux analyzer (Seahorse Bio-
science). The data represent the outcome of an experimental run before nor-
malization. Bar charts showing (B) basal respiration, (C) maximal Respiratory
capacity, and (D)ATPproduction.Dataare theaverageof 3biological replicates, n
= 30–50 measurements. OCR were normalized to the number of cells and
expressed as percentage of control. Error bars represent SEM, ***p < 0.0005,
****p<0.0001byunpairedStudent t test. (E) Linear regressionof the timecourse
analysis of reactive oxygen species production measured by DCFDA in cultured
fibroblasts. Error bars represent SEM, statistical analysis performed by paired t
test. Color code as in A. ANT = antimycin; FCCP = carbonyl cyanide 4-(tri-
fluoromethoxy) phenylhydrazone; ns = nonsignificant; OCR = oxygen con-
sumption rates; OLIGO = oligomycin; ROT = rotenone; SEM = standard error of
the mean.
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signiﬁcant diﬀerence between the level of ROS produced
between P1 and P3 (p = 0.1039).
Mitochondrial morphology
Mitochondrial morphology in the cultured ﬁbroblasts of P1
and P3 was normal (e-methods and ﬁgure e-2, links.lww.com/
NXG/A201).
Discussion
These data conﬁrm the pathogenic eﬀects of 1 novel
(m.8782G>A) and 1 previously reported (m.8618dup) heter-
oplasmic truncating mutation in MT-ATP6. The frameshift
caused by the m.8618dup results in a premature downstream
stop codon (TAA) 7 while the m.8782G>A mutation changes
GGA to AGA, the structural consequences of which are
thought to cause either a stop codon or a ribosomal frameshift-
1.15 Assuming the ribosomal frameshift mechanism, a stop
codon 31 amino acids downstream to the mutation is pre-
dicted, thereby creating a truncated protein. We also expand
the clinical phenotypic spectrum of mitochondrial ATP syn-
thase disorders to include (1) leukodystrophy and cognitive
decline, with predominant posterior white matter abnormali-
ties, and severely impaired kidney function requiring renal
transplantation caused by m.8618dup; p.(Thr33Hisfs*32) and
(2) myoclonic epilepsy with ataxia associated with
m.8782G>A; p.(Gly86*).
The majority of mitochondrial ATP6 synthase disorders
result from missense mutation in MT-ATP6; moderate
mutant levels (70%–90%) present with early onset ataxia,
learning diﬃculties, and retinal involvement while patients
with higher mutant loads (>90%) develop maternally
inherited Leigh syndrome. Signiﬁcant clinical overlap exists
between the 4 previously and 3 newly reported patients
harboring truncating MT-ATP6 mutations and those with
missense MT-ATP6 variants. However, additional features,
including cerebral white matter changes and renal impair-
ment (4 of 6 and 3 of 6 patients with data available exhibited
these clinical manifestations, table), are reported more
frequently.7–9,16 White matter abnormalities are not un-
common in Leigh syndrome17; however, ATP synthase
dysfunction has been reported with this clinic-radiologic
association infrequently17,18 while chronic kidney disease
with isolated proteinuria, which did not require renal re-
placement therapy, has been reported in a single case of
NARP.19 P2 presented with myoclonic epilepsy with RRF
(MERRF)-like phenotype, typically associated with the
m.8344A>G in MT-TK. Of interest the previously reported
truncating MT-ATP6 mutation m.9127-9128delAT;
p.(Ile201Profs*2) was associated with myoclonic epilepsy,
ataxia, and cerebellar atrophy, although the muscle biopsy
did not reveal RRF.9 The phenotype was considered con-
sistent with NARP, despite no evidence of neuropathy.
Consequently, we suggest truncating MT-ATP6 mutations
should be excluded in patients presenting with a MERRF-
like phenotype if genetic analysis for more well-recognized
causes, such as the m.8344A>G mutation, are negative.
Muscle histopathology is generally unhelpful when di-
agnosing mitochondrial ATP synthase disorders caused by
missense mutations in MT-ATP6/8, and this also applies to
MT-ATP6 truncating mutations (table). Of note, EM dem-
onstrated simpliﬁed cristae structure in the muscle of P3,
a ﬁnding reported in the ﬁbroblasts of a patient harboring the
truncating MT-ATP6 mutation m.8611insC; p.(Pro29-
Leufs*36).8 This observation potentially relates to the
physiologic role that ATP synthase plays in cristae
formation.20
One further important consideration when counseling
patients with truncating MT-ATP6 mutations is that mutant
load varies considerably across diﬀerent tissues unlike the
most commonMT-ATP6missense mutations.3,4 As such, the
level of mutation detectable in blood and/or muscle may not
be representative of peripheral and central nervous tissue,
a factor that potentially explains the discordant clinical syn-
dromes associated with the m.8618dup; p.(Thr33Hisfs*32)
mutation: spastic tetraparesis, posterior leukodystrophy,
cognitive decline, and severe renal disease in P3, and a pre-
viously reported case of NARP.7 Furthermore, given the
variability in mutant load tissue observed for the MT-ATP6
truncating mutations, accurate correlation between hetero-
plasmy levels and disease severity was not possible. Finally,
blood m.8618dup mutant levels were low in both cases: 11%
blood vs 71% muscle (P3) and 26% blood vs 85% muscle.7
These data highlight the importance of undertakingmolecular
analysis in multiple tissue types, given the variable segregation
truncating MT-ATP6 mutations exhibit.
Patient-derived ﬁbroblasts (P1 and P3) andmuscle sample (P2
and P3) were used to demonstrate the downstream eﬀects of
the m.8782G>A; p.(Gly86*) and m.8618dup;
p.(Thr33Hisfs*32) mutations on complex V assembly and
OXPHOS. BNGE analysis of mitochondria from patients’
ﬁbroblasts conﬁrmed the presence of the F1 subcomplexes (x,
y, and z) that were previously reported in Rho0 cells, patient-
derived mutant MT-ATP6 cell lines, and mtDNA depletion
syndrome (ﬁgure 2A).4,14 The presence of fully assembled
complex V, with detectable ATP6, in the patients’ ﬁbroblasts
and skeletal muscle, is consistent with the heteroplasmic state
of the MT-ATP6 mutations (P1 27%, P3 45% mutant loads in
ﬁbroblasts; P2 71% and P3 65% in the muscle; ﬁgure 2, C and
D). The level of ATP6 protein incorporated into complex V
was reduced compared with the control in muscle samples
(ﬁgure 2D). When steady state of ATP6 protein in muscle
sample was evaluated, we conﬁrm the reduction of ATP6
protein (ﬁgure 2E) as reported in a previous case with the same
mutation found in P3.7 Cybrid cell lines conﬁrmed the dele-
terious eﬀect of the new m.8782G>A mutation, while micro-
scale oxygraphy demonstrated that both mutations reduce
basal respiration and ATP synthesis and increase ROS pro-
duction, ﬁndings previously reported with MT-ATP6
mutations.21,22 This bioenergetic proﬁle is consistent with
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Table Clinical, molecular, and functional characteristics of reported truncating MT-ATP6 mutations
Nucleotide
change
Amino acid
change
Clinical phenotype (age last
examined) Brain MRI (age) EMG/NCS
Muscle
histopathology
Proband
heteroplasmy
Maternal
heteroplasmy BNGE Reference
m.8611insC p.(Pro29Leufs*36) Ataxia, microcephaly,
developmental delay, intellectual
disability (9 y)
Normal (2 y) N/A N/A 80% (F)
60% (M)
0% (B)
0% (Bu)
Impaired CV
assembly
(subcomplexes)
F, M
Jackson
et al.8
m.8618dup p.(Thr33Hisfs*32) Developmental delay, headache,
hearing loss, bilateral optic
atrophy and mild retinal
pigmentation, ataxia, cramps (40 y)
Cerebellar atrophy and diffuse
cortical atrophy, hyperintensity
of basal ganglia and diffuse
hyperintensities of white matter
(N/A)
Axonal
neuropathy
No COX −ve or
RRF
85% (M)
26% (B)
0% Impaired CV
assembly
(subcomplexes)
M
Lopez-
Gallardo
et al.7
m.8618dup p.(Thr33Hisfs*32) Developmental delay, learning
difficulties, bilateral cataracts,
tapetoretinal degeneration, ataxia,
spastic paraparesis, hearing loss,
kidney failure, diabetes (40 y)
Cerebellar atrophy, white matter
abnormalities (40 y)
N/A Myopathic
features;
increased lipid
content
65% (M)
45% (F)
20% (B)
12% (U)
4% (B)
Impaired CV
assembly
(subcomplexes)
F, M
P3
(present
study)
m.8719 G > Ab p.(Gly65*) Suspected mitochondrial disease. N/A N/A N/A N/A N/A N/A Tang
et al.16
m.8782 G > Ab p.(Gly86*) Microcephaly, diabetes, focal
segmental glomerulosclerosis,
hearing loss, muscle cramps,
ataxia, focal seizuresa (36 y)
Mesial temporal sclerosis,
reduced brain volume, marked
global cerebellar and brainstem
atrophy and multiple deep and
periventricular white matter
changes (37 y)
No
neuropathy
N/A 53% (U)
31% (B)
27% (F)
0% (B) Impaired CV
assembly
(subcomplexes)
F
P1
(present
study)
m.8782 G > Ab p.(Gly86*) Cognitive impairment, myoclonic
epilepsy, bilateral cataract, ataxia,
hearing loss (38 y)
Cerebellar and brainstem
atrophy, white matter
abnormalities (38 y)
No
neuropathy
Myopathic
features; single
COX –ve and
RRF
71% (M)
28% (U)
12% (F)
11% (B)
0% (M)
0% (U)
0% (B)
Impaired CV
assembly
(subcomplexes)
M
P2
(present
study)
m.9127-
9128delAT
p.(Ile201Profs*2) Hearing loss, myoclonic epilepsy,
ataxia, weakness, fatigue,
hypogonadism, hypothyroidism,
adrenal insufficiency, short
stature, proteinuria, optic atrophy,
retinopathy (24 y)
Cerebellar atrophy, bilateral and
symmetric lesions of the basal
ganglia and pituitary
atrophy (10 y)
No
neuropathy
No COX –ve or
RRF
82% (M)
50% (F)
10% (B)
0% (B, Bu, U) N/A Mordel
et al.9
Abbreviations: B = blood; BNGE =blue-native gel electrophoresis; Bu =Buccal; COX −ve = cytochrome c oxidase deficient fiber, F = fibroblasts; M =muscle; NCS = nerve conduction study; P1 = patient 1; P2 = patient 2; P3 = patient
3; RRF = ragged red fibers; U = urine.
a Focal seizures were in keeping with left sided mesial temporal sclerosis.
b Both stop mutations cause a change from GGA to AGA, the structural consequences of which are debated to cause either a stop codon or a ribosomal frameshift -1.15 Assuming the ribosomal frameshift mechanism a stop
codon 31 amino acids after the mutation is predicted, thereby creating a truncated protein.
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impaired ATP synthase activity and is recapitulated using oli-
gomycin treatment in wild-type cells.23 Reduced complex V
activity is also linked to an increase inmitochondrial membrane
potential. This stimulates an electron leak within the RC and
generates high ROS levels.23,24 It is possible that this mecha-
nism is also contributing to the high ROS levels exhibited by
the ﬁbroblasts of P1 and P3. Finally, maximal respiration ca-
pacity, as determined by the mitochondrial electron transport
chain enzymes (complexes I–IV), was retained in the mutant
cell lines, consistent with an isolated defect of ATP synthase
function. Reducedmaximum respiratory capacity is reported in
the mutant cell lines harboring high levels of m.8993T>C/G.25
However, this is partly explained by the presence of additional
mtDNA variations that compounded the RC defect, as shown
in cybrids models.26 The relatively low MT-ATP6 mutant
levels, or possibly an eﬃcient background bioenergetic proﬁle,
might account for the normality of the respiratory capacity in
our patient-derived ﬁbroblasts.
We expand the molecular and phenotypic spectrum of mi-
tochondrial ATP6 synthase disorders by reporting the clin-
icoradiological, structural, and functional characteristics of 1
novel and 1 maternally inherited heteroplasmic truncating
MT-ATP6 mutation and highlight the variable tissue segre-
gation of these variants, which should be considered when
counseling patients.
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